Faeth Therapeutics, Inc. Payments for Restructuring
Faeth Therapeutics, Inc. (FTH) reported Payments for Restructuring of $382.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-08-04
- Faeth Therapeutics, Inc. payments for restructuring for the quarter ending 2026-06-30 was $382.00K, a 193.85% increase year-over-year.
- Faeth Therapeutics, Inc. payments for restructuring for the quarter ending 2026-03-31 was $435.00K, a 20.17% increase year-over-year.
- Faeth Therapeutics, Inc. payments for restructuring for the quarter ending 2025-12-31 was $512.00K.
- Faeth Therapeutics, Inc. payments for restructuring for the quarter ending 2025-09-30 was $0.00.
- Faeth Therapeutics, Inc. payments for restructuring for fiscal 2024 was $278.00K.
- Faeth Therapeutics, Inc. payments for restructuring for fiscal 2022 was $103.00K.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2026-06-30 | $382.00K 10-Q · filed 2026-08-04 | $817.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.33M derived: sum of 3 quarters · filed 2026-08-04 | $1.33M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $435.00K 10-Q · filed 2026-08-04 | $947.00K derived: sum of 2 quarters · filed 2026-08-04 | $947.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $512.00K 10-K · filed 2026-03-30 | $512.00K derived: sum of 2 quarters · filed 2026-03-30 | $642.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $0.00 10-K · filed 2026-03-30 | $130.00K derived: sum of 2 quarters · filed 2026-08-04 | $492.00K derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $130.00K 10-Q · filed 2026-08-04 | $492.00K derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $362.00K 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $278.00K 10-K · filed 2026-03-30 | |||
| 2023-06-30 | $36.00K 10-K · filed 2024-02-29 | $1.16M derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2023-03-31 | $1.13M 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $103.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |